Quoin Pharmaceuticals (QNRX) News Today $20.50 +12.34 (+151.23%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$15.64 -4.86 (-23.71%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Quoin Pharmaceuticals Up Today?Toggle Visibility of Why Is Quoin Pharmaceuticals Up Today?Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares jumped sharply today after the company announced a private placement financing of up to $104.5 million, attracting leading healthcare-focused institutional investors. Trading volatility triggered multiple limit-up/limit-down (LULD) pauses as the stock surged roughly 300% on the news. Positive Sentiment: Announced private placement financing of up to $104.5 million, led by healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital. News Release Positive Sentiment: Stock soared approximately 300% following the announcement, reflecting strong investor demand for the premium-priced funding. MSN TopStocks Positive Sentiment: Investing.com coverage highlighted the company’s ability to secure premium‐priced funding, further bolstering market sentiment. Investing.com Neutral Sentiment: Shares experienced multiple intraday trading halts due to LULD pauses, underscoring heightened volatility around the financing news. Neutral Sentiment: Short‐interest data as of October 9 showed a days-to-cover ratio of 0.0 despite reporting a spike, indicating minimal actual short‐selling activity to date. Posted 1+ days agoAI Generated. May Contain Errors. QNRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Quoin Pharmaceuticals announces private placement financing up to $104.5MOctober 10 at 3:11 PM | msn.comQNRX Stock Soars 300% After $104.5M Financing Through Private PlacementOctober 10 at 3:11 PM | msn.comQuoin Pharmaceuticals stock soars after securing premium-priced fundingOctober 10 at 10:10 AM | au.investing.comQuoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 MillionOctober 10 at 9:24 AM | globenewswire.comQuoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton SyndromeSeptember 9, 2025 | globenewswire.comQuoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate UpdateSeptember 3, 2025 | theglobeandmail.comQuoin Pharmaceuticals Announces CFO Departure AgreementAugust 27, 2025 | msn.comQuoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton SyndromeAugust 21, 2025 | markets.businessinsider.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyAugust 18, 2025 | finanznachrichten.deQuoin Pharmaceuticals appoints Lawlor as Chief Financial OfficerAugust 18, 2025 | msn.comQuoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyAugust 18, 2025 | globenewswire.comQuoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-EastonAugust 12, 2025 | globenewswire.comQNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate TimelineAugust 8, 2025 | finance.yahoo.comQuoin (QNRX) Q2 Loss Beats EstimatesAugust 7, 2025 | fool.comQuoin Pharmaceuticals stock rises after positive clinical updatesJuly 31, 2025 | investing.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | finanznachrichten.deQuoin Pharmaceuticals Provides Product Portfolio UpdateJuly 29, 2025 | globenewswire.comQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - MorningstarJune 27, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - NasdaqJune 27, 2025 | nasdaq.comQNRX - Quoin Pharmaceuticals Ltd ADR Executives - MorningstarJune 26, 2025 | morningstar.comMQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin DiseasesJune 26, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton SyndromeJune 24, 2025 | tmcnet.comQuoin Pharmaceuticals, Ltd. (QNRX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comQNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30, 2025 | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30, 2025 | globenewswire.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comQuoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comQuoin announces additional data from Pediatric Netherton Syndrome studyApril 3, 2025 | markets.businessinsider.comQuoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for DosingApril 2, 2025 | reuters.comQuoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientApril 2, 2025 | globenewswire.comQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMarch 25, 2025 | globenewswire.comQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26March 18, 2025 | msn.comQuoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last yearMarch 13, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsMarch 13, 2025 | globenewswire.comQNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the DiseaseMarch 5, 2025 | msn.comQuoin files U.S., International patent applications for rapamycin formulationsMarch 4, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease IndicationsMarch 4, 2025 | globenewswire.comQuoin Pharmaceuticals’ QRX003 shows potential efficacy in Netherton SyndromeFebruary 28, 2025 | markets.businessinsider.comQuoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFebruary 27, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFebruary 27, 2025 | globenewswire.comQuoin Pharmaceuticals launches first episode of ‘NETHERTON NOW’ seriesFebruary 25, 2025 | markets.businessinsider.com Get Quoin Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNRX Media Mentions By Week QNRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNRX News Sentiment▼0.100.76▲Average Medical News Sentiment QNRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNRX Articles This Week▼252▲QNRX Articles Average Week Get the Latest News and Ratings for QNRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Quoin Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ICU News Today CTCX News Today NXL News Today ALUR News Today SINT News Today IINN News Today CODX News Today OSRH News Today BTCY News Today XAIR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNRX) was last updated on 10/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
